Join a Clinical Trial
Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each clinical trial.
Clinical Trial Details
A Study of Subcutaneous Blinatumomab Administration in Acute Lymphoblastic Leukemia (ALL) Patients
Complete Title: A Phase 1b Open-label Study to Investigate the Safety and Pharmacokinetics of Administration of
Subcutaneous Blinatumomab for the Treatment of adults with Relapsed or Refractory B cell Precursor
Acute Lymphoblastic Leukemia (R/R B-ALL)
Trial Phase: I/II
Investigator: Ryan Cassaday
The study aims to evaluate the safety and tolerability of subcutaneous (SC) blinatumomab for treatment of Acute Lymphoblastic Leukemia (ALL) and to determine the maximum tolerated dose (MTD), and recommended phase 2 dose (RP2D) of SC administered blinatumomab.
Keywords:
- Leukemia, B-Cell, Lymphoblastic
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.
Contact Us
If you are seeking to schedule an appointment, we are here to help. You can either call us or fill out our online appointment request form.
Adult
I/II
Ryan Cassaday
RG1007298
NCT04521231
A Phase 1b Open-label Study to Investigate the Safety and Pharmacokinetics of Administration of
Subcutaneous Blinatumomab for the Treatment of adults with Relapsed or Refractory B cell Precursor
Acute Lymphoblastic Leukemia (R/R B-ALL)
Leukemia, B-Cell, Lymphoblastic